Home Pulmonx Corp.

Pulmonx Corp.

Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valve

The Zephyr Valve procedure, done through a simple bronchoscopy with no incision or cutting, is clinically proven to improve patients’ breathing, exercise capacity, and quality of life, without the risks of major surgery.

FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema

7/2/18: “Zephyr Valves are a major step forward in treating severe emphysema patients who consistently feel short of breath despite all the medications we can offer. I have seen Zephyr Valve-treated patients getting back to a more active life doing the things they enjoy. As a physician, it is very gratifying to have a new treatment that can restore a patient’s confidence and change their life for the long term,” said Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, and lead investigator for the LIBERATE Study.

Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial

5/23/18: Study met all primary and secondary endpoints across multiple measures of breathing and quality of life one year after treatment.